Chinese Journal of Antituberculosis ›› 2026, Vol. 48 ›› Issue (5): 716-622.doi: 10.19982/j.issn.1000-6621.20250474
• Review Articles • Previous Articles Next Articles
Lai Xiaoyu, Liao Qinghua, Wen Wenpei(
), Guo Huixin, Lin Weibin, Chen Xunxun(
)
Received:2025-12-02
Online:2026-05-10
Published:2026-04-27
Contact:
Wen Wenpei,Chen Xunxun
E-mail:grace_chen514@163.com;wwp_yb@126.com
Supported by:CLC Number:
Lai Xiaoyu, Liao Qinghua, Wen Wenpei, Guo Huixin, Lin Weibin, Chen Xunxun. Advances in the research on the pathogenesis of tuberculous uveitis[J]. Chinese Journal of Antituberculosis, 2026, 48(5): 716-622. doi: 10.19982/j.issn.1000-6621.20250474
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20250474
| [1] | Alli HD, Ally N, Mayet I, et al. Global prevalence and clinical outcomes of tubercular uveitis: a systematic review and meta-analysis. Surv Ophthalmol, 2022, 67(3):770-792. doi:10.1016/j.survophthal.2021.10.001. |
| [2] |
Standardization of Uveitis Nomenclature (SUN) Working Group. Classification Criteria for Tubercular Uveitis. Am J Ophthalmol, 2021, 228:142-151. doi:10.1016/j.ajo.2021.03.040.
URL pmid: 33845014 |
| [3] |
Aggarwal K, Agarwal A, Deokar A, et al. Ultra-Wide Field Imaging in Paradoxical Worsening of Tubercular Multifocal Serpiginoid Choroiditis after the Initiation of Anti-Tubercular Therapy. Ocul Immunol Inflamm, 2019, 27(3):365-370. doi:10.1080/09273948.2017.1373829.
URL pmid: 29020501 |
| [4] | Betzler BK, Gunasekeran DV, Kempen J, et al. The Historical Evolution of Ocular Tuberculosis: Past, Present, and Future. Ocul Immunol Inflamm, 2022, 30(3):593-599. doi:10.1080/09273948.2021.1992446. |
| [5] |
Agrawal R, Gunasekeran DV, Grant R, et al. Clinical Features and Outcomes of Patients With Tubercular Uveitis Treated With Antitubercular Therapy in the Collaborative Ocular Tuberculosis Study (COTS)-1. JAMA Ophthalmol, 2017, 135(12):1318-1327. doi:10.1001/jamaophthalmol.2017.4485.
URL pmid: 29075752 |
| [6] | Albert DM, Raven ML. Ocular tuberculosis. Microbiol Spectr, 2016, 4 (6):TNMI7-0001-2016. doi:10.1128/microbiolspec.TNMI7-0001-2016. |
| [7] | Koch R. Professor Koch’s remedy for tuberculosis: A further communication on a remedy for tuberculosis. Indian J Med Res, 2023, 157(2/3):169-173. doi:10.4103/0971-5916.373948. |
| [8] |
Woods AC, Wood RM, Naquin HA. Studies in experimental ocular tuberculosis. Effect of streptomycin and promizole in experimental ocular tuberculosis in the normal rabbit. Arch Ophthal, 1950, 43(5):834-844.
pmid: 15414081 |
| [9] | Coelho Filho JC, Takenami I, Arruda S. Revisiting the Rich’s formula: an update about granulomas in human tuberculosis. Braz J Infect Dis, 2013, 17(2):234-238. doi:10.1016/j.bjid.2013.01.006. |
| [10] | Abdisamadov A, Tursunov O. Ocular tuberculosis epidemiology, clinic features and diagnosis: A brief review. Tuberculosis (Edinb), 2020, 124:101963. doi:10.1016/j.tube.2020.101963. |
| [11] | Chawla R, Singh MK, Singh L, et al. Tubercular DNA PCR of ocular fluids and blood in cases of presumed ocular tuberculosis: a pilot study. Ther Adv Ophthalmol, 2022, 14:25158414221123522. doi:10.1177/25158414221123522. |
| [12] | Sharma K, Sharma M, Joshi H, et al. Evaluation of Mycobacterium Tuberculosis Derived Cell-Free DNA-Based Multi-Targeted Real-Time PCR from Vitreous Fluid (VF) Samples to Diagnose Ocular Tuberculosis. Ocul Immunol Inflamm, 2025, 33(9):1907-1912. doi:10.1080/09273948.2025.2532820. |
| [13] | Putera I, Schrijver B, Ten Berge JCEM, et al. The immune response in tubercular uveitis and its implications for treatment: From anti-tubercular treatment to host-directed therapies. Prog Retin Eye Res, 2023, 95:101189. doi:10.1016/j.preteyeres.2023.101189. |
| [14] | Damera SK, Panigrahi RK, Mitra S, et al. Role of Extracellular Mycobacteria in Blood-Retinal Barrier Invasion in a Zebrafish Model of Ocular TB. Pathogens, 2021, 10(3):333. doi:10.3390/pathogens10030333. |
| [15] | Dalvin LA, Smith WM. Intraocular manifestations of mycobacterium tuberculosis: A review of the literature. J Clin Tuberc Other Mycobact Dis, 2017, 7:13-21. doi:10.1016/j.jctube.2017.01.003. |
| [16] |
Aggarwal K, Agarwal A, Sehgal S, et al. An unusual presentation of intraocular tuberculosis in a monocular patient: clinicopathological correlation. J Ophthalmic Inflamm Infect, 2016, 6 (1): 46. doi:10.1186/s12348-016-0118-8.
URL pmid: 27888495 |
| [17] | Basu S, Elkington P, Rao NA. Pathogenesis of ocular tuberculosis: New observations and future directions. Tuberculosis (Edinb), 2020, 124:101961. doi:10.1016/j.tube.2020.101961. |
| [18] |
Yeh S, Sen HN, Colyer M, et al. Update on ocular tuberculosis. Curr Opin Ophthalmol, 2012, 23(6):551-556. doi:10.1097/ICU.0b013e328358ba01.
URL pmid: 23047173 |
| [19] |
Kataria P, Kumar A, Bansal R, et al. devR PCR for the diagnosis of intraocular tuberculosis. Ocul Immunol Inflamm, 2015, 23(1):47-52. doi:10.3109/09273948.2014.981550.
URL pmid: 25615810 |
| [20] | Sharma K, Gupta A, Sharma M, et al. Detection of viable Mycobacterium tuberculosis in ocular fluids using mRNA-based multiplex polymerase chain reaction. Indian J Med Microbiol, 2022, 40(2):254-257. doi:10.1016/j.ijmmb.2021.12.019. |
| [21] |
Konana VK, Babu K. Current concepts in the diagnosis of ocular tuberculosis: A narrative review. Taiwan J Ophthalmol, 2025, 15 (2): 203-211. doi:10.4103/tjo.TJO-D-24-00115.
URL pmid: 40584192 |
| [22] |
Balne PK, Modi RR, Choudhury N, et al. Factors influencing polymerase chain reaction outcomes in patients with clinically suspected ocular tuberculosis. J Ophthalmic Inflamm Infect, 2014, 4(1):10. doi:10.1186/1869-5760-4-10.
URL pmid: 24661354 |
| [23] | Kaur K, Laal S, Ryndak MB. Mycobacterium tuberculosis transcriptome in intraocular tuberculosis. J Med Microbiol, 2023, 72(2). doi:10.1099/jmm.0.001649. |
| [24] |
Ganesh SK, Abraham S, Sudharshan S. Paradoxical reactions in ocular tuberculosis. J Ophthalmic Inflamm Infect, 2019, 9(1):19. doi:10.1186/s12348-019-0183-x.
URL pmid: 31493128 |
| [25] |
Ohara H, Harada Y, Hiyama T, et al. Incidence of ocular inflammation among patients with active tuberculosis or nontuberculous mycobacterial infections in a tertiary hospital in Japan. Int Ophthalmol, 2021, 41(4):1427-1436. doi:10.1007/s10792-021-01718-z.
URL pmid: 33475908 |
| [26] | Multani PK, Modi R, Basu S. Pattern of Recurrent Inflammation following Anti-tubercular Therapy for Ocular Tuberculosis. Ocul Immunol Inflamm, 2022, 30(1):185-190. doi:10.1080/09273948.2020.1772838. |
| [27] | Fernández-Zamora Y, Finamor LP, Silva LMP, et al. Role of Interferon-Gamma Release Assay for the Diagnosis and Clinical Follow up in Ocular Tuberculosis. Ocul Immunol Inflamm, 2023, 31(2):304-311. doi:10.1080/09273948.2022.2027459. |
| [28] | Alam K, Sharma G, Forrester JV, et al. Antigen-Specific Intraocular Cytokine Responses Distinguish Ocular Tuberculosis From Undifferentiated Uveitis in Tuberculosis-Immunoreactive Patients. Am J Ophthalmol, 2023, 246:31-41. doi:10.1016/j.ajo.2022.08.029. |
| [29] | Shree R, Mahesh KV, Takkar A, et al. The Neuro-Ophthalmology of Tuberculosis. Neuroophthalmology, 2023, 48(2):73-92. doi:10.1080/01658107.2023.2281435. |
| [30] | Gusmão CC, Dos Reis R, Litvoc MN, et al. Paradoxical Reaction in Intraocular Tuberculosis: Report of Three Cases. Ocul Immunol Inflamm, 2024, 32(10):2562-2567. doi:10.1080/09273948.2024.2372314. |
| [31] | Kon OM, Beare N, Connell D, et al. BTS clinical statement for the diagnosis and management of ocular tuberculosis. BMJ Open Respir Res, 2022, 9(1):e001225. doi:10.1136/bmjresp-2022-001225. |
| [32] | Biswas J, Therese L, Madhavan HN. Use of polymerase chain reaction in detection of Mycobacterium tuberculosis complex DNA from vitreous sample of Eales’ disease. Br J Ophthalmol, 1999, 83(8):994. doi:10.1136/bjo.83.8.994. |
| [33] | Agrawal R, Testi I, Rousselot A, et al. Insights into the molecular pathogenesis of ocular tuberculosis. Tuberculosis (Edinb), 2021, 126:102018. doi:10.1016/j.tube.2020.102018. |
| [34] | Nandi K, Panda AK, Chakraborty A, et al. Role of ATP-Small Heat Shock Protein Interaction in Human Diseases. Front Mol Biosci, 2022, 9:844826. doi:10.3389/fmolb.2022.844826. |
| [35] | Kutlutürk Karagöz I, Kaya M, Kıvrak U, et al. Exploring the Molecular Intersection of Posterior Ocular Tuberculosis: Mycobacterium tuberculosis Proteins, Ocular Autoimmunity, and Immune Receptor Interactions. Ophthalmol Sci, 2024, 5(3):100698. doi:10.1016/j.xops.2024.100698. |
| [36] |
Wroblewski KJ, Hidayat AA, Neafie RC, et al. Ocular tuberculosis: a clinicopathologic and molecular study. Ophthalmology, 2011, 118(4):772-777. doi:10.1016/j.ophtha.2010.08.011.
URL pmid: 21055814 |
| [37] | Adamus G. Are Anti-Retinal Autoantibodies a Cause or a Consequence of Retinal Degeneration in Autoimmune Retinopa-thies?. Front Immunol, 2018, 9:765. doi:10.3389/fimmu.2018.00765. |
| [38] | Wildner G, Diedrichs-Möhring M. Molecular Mimicry and Uveitis. Front Immunol, 2020, 11:580636. doi:10.3389/fimmu.2020.580636. |
| [39] | Zhang YK, Guan Y, Zhao J, et al. Diagnosis of tuberculous uveitis by the macrogenome of intraocular fluid: A case report and review of the literature. World J Clin Cases, 2023, 11(14):3248-3255. doi:10.12998/wjcc.v11.i14.3248. |
| [40] |
Papasavvas I, Jeannin B, Herbort CP. Tuberculosis-related serpiginous choroiditis: aggressive therapy with dual concomitant combination of multiple anti-tubercular and multiple immunosuppressive agents is needed to halt the progression of the disease. J Ophthalmic Inflamm Infect, 2022, 12(1):7. doi:10.1186/s12348-022-00282-6.
URL pmid: 35132499 |
| [41] | Brar M, Sharma M, Grewal S, et al. Longitudinal study of serpiginous choroiditis and serpiginous like choroiditis using wide field OCT angiography. Eur J Ophthalmol, 2022, 32(3):1555-1561. doi:10.1177/11206721211028529. |
| [42] | Shah JS, Shetty N, Shah SK, et al. Tubercular Uveitis with Ocular Manifestation as the First Presentation of Tuberculosis: A Case Series. J Clin Diagn Res, 2016, 10(3):NR01-3. doi:10.7860/JCDR/2016/16219.7375. |
| [43] | 赖晓宇, 段鸿飞, 陈珣珣, 等. 结核性葡萄膜炎临床特征,诊断策略与分级标准研究进展. 中国防痨杂志, 2025, 47(9):1204-1211. doi:10.19982/j.issn.1000-6621.20250196. |
| [44] | Welin A, Björnsdottir H, Winther M, et al. CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor. Infect Immun, 2015, 83(1):205-213. doi:10.1128/IAI.02493-14. |
| [45] |
Renshaw PS, Lightbody KL, Veverka V, et al. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. EMBO J, 2005, 24(14):2491-2498. doi:10.1038/sj.emboj.7600732.
URL pmid: 15973432 |
| [46] | van Leeuwen LM, Boot M, Kuijl C, et al. Mycobacteria employ two different mechanisms to cross the blood-brain barrier. Cell Microbiol, 2018, 20(9):e12858. doi:10.1111/cmi.12858. |
| [47] | Liu R, Dang JN, Lee R, et al. Mycobacterium dormancy and antibiotic tolerance within the retinal pigment epithelium of ocular tuberculosis. Microbiol Spectr, 2024, 12(8):e0078824. doi:10.1128/spectrum.00788-24. |
| [48] | 程奕喆, 呼风, 王茹, 等. 结核性葡萄膜炎患者房水的细胞因子含量研究. 眼科, 2023, 32(2):135-141. doi:10.13281/j.cnki.issn.1004-4469.2023.02.009. |
| [49] |
Ang M, Cheung G, Vania M, et al. Aqueous cytokine and chemokine analysis in uveitis associated with tuberculosis. Mol Vis, 2012, 18:565-573.
pmid: 22509092 |
| [50] | Putera I, La Distia Nora R, Ten Berge JCEM, et al. Diagnostic Biomarkers for Uveitis: Serum BAFF and CXCL 9 in Differentiating Ocular Sarcoidosis, Tuberculosis and Other Entities with Implication for QuantiFERON-Positive Uveitis. Ocul Immunol Inflamm, 2025, 33(8):1548-1560. doi:10.1080/09273948.2025.2493357. |
| [51] | Valenzuela RA, Vega-Tapia F, Elizalde N, et al. IL-10 and IL-6/IL-10 as predictive biomarkers for treatment response in non-infectious uveitis. Front Immunol, 2025, 16:1584905. doi:10.3389/fimmu.2025.1584905. |
| [52] | Chadalawada S, Kathirvel K, Lalitha P, et al. Dysregulated expression of microRNAs in aqueous humor from intraocular tuberculosis patients. Mol Biol Rep, 2022, 49(1):97-107. doi:10.1007/s11033-021-06846-4. |
| [53] | Davuluri KS, Chauhan DS. microRNAs associated with the pathogenesis and their role in regulating various signaling pathways during Mycobacterium tuberculosis infection. Front Cell Infect Microbiol, 2022, 12:1009901. doi:10.3389/fcimb.2022.1009901. |
| [54] |
Li R, Zheng SG, Zhou H. Metabolomics of ocular immune diseases. Metabolomics, 2025, 21(3):74. doi:10.1007/s11306-025-02273-9.
URL pmid: 40457094 |
| [55] | 肖媛媛, 毛羽, 曹绪胜, 等. 结核性葡萄膜炎初始抗结核治疗矛盾反应的临床特征. 眼科, 2022, 31(4):277-281. doi:10.13281/j.cnki.issn.1004-4469.2022.04.006. |
| [56] | Quinn CM, Poplin V, Kasibante J, et al. Tuberculosis IRIS: Pathogenesis, Presentation, and Management across the Spectrum of Disease. Life (Basel), 2020, 10(11):262. doi:10.3390/life10110262. |
| [57] | Nieto-Aristizábal I, Mera JJ, Giraldo JD, et al. From ocular immune privilege to primary autoimmune diseases of the eye. Autoimmun Rev, 2022, 21(8):103122. doi:10.1016/j.autrev.2022.103122. |
| [58] | Woodward R, Konda SM, Grewal DS. Autoimmune Inflammatory Eye Disease: Demystifying Clinical Presentations for the Internist. Curr Allergy Asthma Rep, 2023, 23(8):471-479. doi:10.1007/s11882-023-01088-9. |
| [59] |
Sharma RK, Sharma J, Khan ZK, et al. Diminished TLR2-TLR9 mediated CD4+ T cell responses are associated with increased inflammation in intraocular tuberculosis. Sci Rep, 2018, 8(1): 13812. doi:10.1038/s41598-018-32234-3.
URL pmid: 30218032 |
| [60] |
Basu S, Hassman L, Kodati S, et al. Intraocular Immune Response in Human Uveitis: Time to Look Beyond Animal Models. Am J Ophthalmol, 2024, 266:17-25. doi:10.1016/j.ajo.2024.04.026.
URL pmid: 38703799 |
| [61] | Tagirasa R, Parmar S, Barik MR, et al. Autoreactive T Cells in Immunopathogenesis of TB-Associated Uveitis. Invest Ophthalmol Vis Sci, 2017, 58(13):5682-5691. doi:10.1167/iovs.17-22462. |
| [1] | Reyhangul·Aken , Muratjan·Amat , Gao Xusheng, Ding Caihong, Zeng Yi, Chen Yu, Bai Yan, Fan Lin. Analysis of influencing factors of malnutrition and treatment outcomes among elderly patients with pulmonary tuberculosis aged 60 years and above [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 751-759. |
| [2] | Jiangxi Chest Hospital/Jiangxi Provincial Key Laboratory of Tuberculosis, Chinese Antituberculosis Association, Guangzhou National Laboratory. Expert consensus on the diagnosis and treatment of breast tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 737-750. |
| [3] | Xu Yong, Zhou Teng, Liu Junjia. Construction and validation of a risk prediction model for restenosis after interventional treatment of tuberculous airway stenosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 760-768. |
| [4] | Fan Jiahua, Yan Liang, Chen Hua, Lu Chunli, Wang Min, Huang Yaling, Li Yan. Association between nutritional risk, inflammatory indicators, and glycemic control in patients with tuberculosis complicated by diabetes mellitus [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 769-778. |
| [5] | Wang Xinyan, Pan Hongfang, Mei Xue, Zhang Yi, Liu Jie. Analysis of the characteristics of peripheral blood clinical detection indicators in patients with pulmonary tuberculosis complicated with osteoarticular tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 779-786. |
| [6] | Li Jing, Chen Shuangshuang, Chen Chunhua, Yang Guoxiang, Yang Chengnao, Zheng Luyun, Tan Chengjian, Li Chuanyou, Li Jie, Zhou Peifu, Dai Xiaowei. Screening of anti-tuberculosis activity and analysis of chemical constituents of the Ethnomedicine Botrychium ternatum [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 787-794. |
| [7] | Xia Lu, Mu Tingting, Cai Qiujie, Ma Yan, Gong Mengmeng, Ye Dan, Zhang Wei. Analysis of Traditional Chinese Medicine syndrome characteristics in 619 severe pulmonary tuberculosis patients based on syndrome element differentiation [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 795-802. |
| [8] | Guo Chenhao, Liu Xinyu, Zhan Sirui, Wang Lili, Ma Mengting, Li Xiumei, Qi Linping, Li Weiping. Interferon-gamma release assays for diagnosing extrapulmonary tuberculosis in adults: a systematic review and Meta-analysis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 803-812. |
| [9] | Zhang Yue, Huang Jinpeng, Gao Dan, Ling Lin. Status and influencing factors of medication adherence among elderly tuberculosis patients based on digital technologies [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 813-820. |
| [10] | Zhang Yaying, Wang Senlu, Guliziba Kuerbanjiang, Abulikemu Aili, Liang Chen, Yuan Shuanglong, Li Caihong, Cao Mingqin. Analysis of influencing factors and pathways on psychological burden associated with pulmonary tuberculosis treatment in Southern Xinjiang Region of the Xinjiang Uygur Autonomous Region [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 821-829. |
| [11] | Du Xilong, Maiwulajiang·Yimamu , Na Yan, Paziliya·Yasheng , Guo Gang, Maiweilanjiang·Abulimiti , Zhang Liping, Zheng Yanling. Construction of an optimal prediction model for treatment outcomes in retreatment pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 830-839. |
| [12] | Liu Lin, Yin Xiaocheng, Zhang Xiaofo, Liang Linlong, Yang Ju. Global burden of tuberculosis in children aged 0-14 years, 1990—2023, and trend projections for 2024—2050 [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 840-848. |
| [13] | Huang Aichun, Lan Yanqun, Xu Chaoyan, Zhang Jie, Li Weiwen, Zhu Qingdong, Xie Zhouhua. Analysis of related factors influencing interferon-gamma release assay results in patients having coexistent tuberculosis and acquired immune deficiency syndrome [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 849-855. |
| [14] | Jiang Xuefeng, Zhou Linjun, Sun Yan, Jiang Mingxia, Ma Ling, Mei Li, Liu Dongxin. Analysis of drug resistance gene mutation characteristics in Mycobacterium tuberculosis strains from five northwestern provinces of China [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 856-864. |
| [15] | Yuan Shaoying, Cui Zhongfeng, Du Jiang, Cao Xuefang, Feng Boxuan, He Yijun, Li Zihan, Zhao Yaqi, Yu Yilin, Gao Lei, Xin He’nan, Li Hongzhi. The application value of the QuantiFERON-TB Gold Plus for active pulmonary tuberculosis diagnosis and treatment response monitoring [J]. Chinese Journal of Antituberculosis, 2026, 48(6): 865-873. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.